1374667-69-2

Basic information

• Product Name: 3-(cyclopropylmethyl)-7-[[(2R)-2-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine
• Synonyms: 3-(cyclopropylmethyl)-7-[[(2R)-2-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine
• CAS NO: 1374667-69-2
• Molecular Weight: 416.446
• Mol File: 1374667-69-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(cyclopropylmethyl)-7-[[(2R)-2-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(cyclopropylmethyl)-7-[[(2R)-2-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine(1374667-69-2)
• EPA Substance Registry System: 3-(cyclopropylmethyl)-7-[[(2R)-2-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine(1374667-69-2)

Safety Data

• Hazardous Substances Data: 1374667-69-2(Hazardous Substances Data)

Upstream product

• 1225376-02-2 (R)-2-phenylmorpholine 
• 1254982-03-0 3-(cyclopropylmethyl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-carbaldehyde 
• 1254982-02-9 7-vinyl-3-(cyclopropylmethyl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine 
• 1254981-30-0 7-chloro-3-(cyclopropylmethyl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine 
• 1254981-29-7 N'-[4-(benzyloxy)-3-(trifluoromethyl)pyridin-2-yl]-2-cyclopropylacetohydrazide 
• 1254981-28-6 4-(benzyloxy)-2-hydrazineyl-3-(trifluoromethyl)pyridine 
• 1254981-27-5 4-(benzyloxy)-2-chloro-3-(trifluoromethyl)pyridine 
• 1186194-98-8 2,4-dichloro-3-(trifluoromethyl)pyridine 
• 343781-36-2 2,4-dichloro-3-iodo-pyridine 
• 26452-80-2 2,4-dichloropyridine 

Relevant articles and documents

1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.